It’s been three-and-a-half years since generative AI exploded onto the scene. In this past year, progress has continued its relentless pace: Vibe coding took off, companies embraced agentic workflows, ...
During the Tanker War of the 1980s, Iran used missiles, mines and speed boats to assert its control over the Strait of Hormuz. Back then, it took an extensive naval operation, including the ...
Laptops are practical because you can take them with you. However, laptops have a relatively small screen. If you work on a mobile computer, it quickly becomes annoying to constantly switch programs.
Add Futurism (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results. In a ...
Oscar-nominated editor Olivier Bugge Coutté also dissects that montage of the characters’ faces that wasn’t in the original script. By Simon Thompson Sentimental Value, director Joachim Trier’s ...
All products featured here are independently selected by our editors and writers. If you buy something through links on our site, Mashable may earn an affiliate commission. However, there's one big ...
Joachim Trier goes deep into the silent ending of his Oscar contender, breaking down how he constructed a script that built toward such a powerful moment. “I’m out on a limb with this one,” said Trier ...
A new study suggests that everyday multilingual habits—from chatting with neighbors to revisiting a childhood language—may help preserve memory, attention, and brain flexibility as we age. An ...
To better understand which social media platforms Americans use, Pew Research Center surveyed 5,022 U.S. adults from Feb. 5 to June 18, 2025. SSRS conducted this National Public Opinion Reference ...
Career advice often revolves around three big ideas: define your values, follow your passion and find your purpose. But as Irina Cozma writes in the Harvard Business Review, “We all know following ...
Blenrep, combined with Velcade and dexamethasone, is approved for relapsed/refractory multiple myeloma after two prior therapies, showing significant survival benefits. The phase 3 DREAMM-7 trial ...